The maximum supply for prescriptions of implantable infusion pumps containing Schedule II or III controlled substances is:

The maximum supply for prescriptions of implantable infusion pumps containing Schedule II or III controlled substances is established as 90 days. This regulation is designed to balance patient needs with the potential risk associated with the use of controlled substances.

Implantable infusion pumps typically deliver medication continuously over a period, which differs significantly from traditional prescriptions that are often for acute conditions. The 90-day limit helps ensure that patients receive a sufficient supply without risking excessive potential for abuse or diversion associated with controlled substances. Additionally, this timeframe allows for proper monitoring of the patient’s response to the treatment, enabling healthcare professionals to adjust dosing or medications as needed.

This regulatory framework is grounded in the broader objectives of controlled substances legislation, which aims to promote safe and effective medication use while preventing misuse. The specifics of this regulation, including the 90-day maximum, are aligned with best practices in patient care and pharmacy jurisprudence. Understanding these parameters is key in the practice of pharmacy to ensure compliance with state and federal laws.